AZN
USDAstraZeneca PLC American Depositary Shares
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$74.610
Kõrge
$75.380
Madal
$74.260
Maht
3.44M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
232.5B
Tööstusharu
Drug Manufacturers - General
Riik
United Kingdom
Kauplemisstatistika
Keskmine maht
5.47M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer
The first patient has been dosed in the DESTINY-Endometrial01 phase 3 trial evaluating ENHERTU® (trastuzumab deruxtecan) in combination with rilvegostomig or pembrolizumab versus platinum-based chemotherapy
Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial
AstraZeneca and Daiichi Sankyo's ENHERTU plus pertuzumab showed a median progression-free survival greater than three years First trial in more than a decade to demonstrate an improvement in outcomes in the 1st-line
Healthcare's Quiet AI Boom Is Creating a New Class of Breakout Contenders
Equity Insider News Commentary – Artificial intelligence is rapidly becoming one of the most promising frontiers in healthcare innovation. Ark...
From Retina Scans to Cancer Trials, AI Is Taking Over the Exam Room
Equity Insider News Commentary – The World Economic Forum recently spotlighted five healthcare breakthroughs, and at the top of the list was...
Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma
AIRSUPRA demonstrated a 47% reduction in the risk of severe exacerbations in mild asthma compared with albuterol alone Full results published in the New England Journal of Medicine and presented at ATS 2025
Seotud aktsiad
HLT
Hilton Worldwide
DIAX
Nuveen Dow 30SM Dynamic Overwrite Fund Common Shares of Beneficial Interest
CMCSA
Comcast Corporation
RTX
RTX Corporation
ERH
Allspring Utilities and High Income Fund Common Shares
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.